[开放获取]    中国天疱疮诊疗指南（2024版）

doi:10.35541/cjd.20240222

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (10): 873-886.doi: 10.35541/cjd.20240222

[开放获取] 中国天疱疮诊疗指南（2024版）

中国医师协会皮肤科医师分会中华医学会皮肤性病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会

中国医师协会皮肤科医师分会中华医学会皮肤性病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会

收稿日期:2024-04-25 修回日期:2024-07-23 发布日期:2024-09-29
通讯作者: 晋红中；王刚 E-mail:jinhongzhong@263.net; xjwgang@fmmu.edu.cn
基金资助:
中央高水平医院临床科研业务费（2022-PUMCH-B-092）；国家重点研发计划项目（2022YFC3601800）；北京市自然科学基金（7242109）；国家临床重点专科建设项目

Guidelines for diagnosis and treatment of pemphigus in China （2024）

China Dermatologist Association; Treatment Group, Chinese Society of Dermatology; Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care; National Clinical Research Center for Dermatologic and Immunologic Diseases; Rare Skin Diseases Committee, China Alliance for Rare Diseases

China Dermatologist Association; Treatment Group, Chinese Society of Dermatology; Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care; National Clinical Research Center for Dermatologic and Immunologic Diseases; Rare Skin Diseases Committee, China Alliance for Rare Diseases

Received:2024-04-25 Revised:2024-07-23 Published:2024-09-29
Contact: Jin Hongzhong; Wang Gang E-mail:jinhongzhong@263.net; xjwgang@fmmu.edu.cn
Supported by:
National High Level Hospital Clinical Research Funding （2022-PUMCH-B-092）; National Key R&D Program of China （2022YFC3601800）; Beijing Natural Science Foundation （7242109）; National Key Clinical Specialty Project of China

摘要/Abstract

摘要： 【摘要】天疱疮是一组少见而严重的自身免疫性大疱性疾病，以皮肤和/或黏膜的水疱、大疱、糜烂为主要临床表现。随着对天疱疮认识的不断深入和治疗手段的不断更新，有必要制订中国天疱疮诊疗指南。由相关学术组织组建的指南工作组，基于国内外现有证据，结合我国国情，经过多轮论证与遴选，形成了关于天疱疮诊断和治疗的12个亟待解决的临床问题和30条推荐意见，为天疱疮的诊断和治疗提供参考，指导临床实践。

关键词: 天疱疮, 诊断, 治疗, 糖皮质激素, 利妥昔单抗, 免疫抑制剂, 指南

Abstract: 【Abstract】 Pemphigus is a group of rare and severe autoimmune bullous diseases characterized by blisters, bullae, and erosions on the skin and/or mucous membranes. With the deep understanding of pemphigus and continuous update of treatment methods, it is necessary to formulate guidelines for the diagnosis and treatment of pemphigus in China. Hence, a guideline working group was established by relevant academic organizations. Based on available evidence in China and other countries, as well as China's national conditions, 12 clinical issues that need to be urgently solved were proposed and 30 recommendations were formulated on the diagnosis and treatment of pemphigus after multiple rounds of demonstration and selection, aiming to provide a reference for the diagnosis and treatment of pemphigus and to guide clinical practice.

Key words: Pemphigus, Diagnosis, Treatment, Glucocorticoids, Rituximab, Immunosuppressive agents, Guideline

中国医师协会皮肤科医师分会中华医学会皮肤性病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会. [开放获取] 中国天疱疮诊疗指南（2024版）[J]. 中华皮肤科杂志, 2024,57(10):873-886. doi:10.35541/cjd.20240222

China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Guidelines for diagnosis and treatment of pemphigus in China （2024）[J]. Chinese Journal of Dermatology, 2024, 57(10): 873-886.doi:10.35541/cjd.20240222

参考文献 74

［1］	中国医师协会皮肤科医师分会, 疑难重症及罕见病国家重点实验室, 国家皮肤与免疫疾病临床医学研究中心. 天疱疮患者健康教育共识（2023版）［J］. 中华皮肤科杂志, 2023:e20230123. doi:10.35541/cjd.20230123:
［2］	Schmidt E, Kasperkiewicz M, Joly P. Pemphigus［J］. Lancet, 2019,394（10201）:882⁃894. doi: 10.1016/S0140⁃6736（19）31778⁃7.
［3］	张晓, 朱冠男, 张少龙, 等. 182例天疱疮患者合并感染状况的回顾分析［J］. 中华皮肤科杂志, 2020,53（1）:8⁃12. doi: 10.35541/cjd.20190382.
［4］	国家卫生健康委，科技部，工业和信息化部, 等.关于公布第二批罕见病目录的通知［J］. 中华人民共和国国家卫生健康委员会公报, 2023,238（9）:11⁃14.
［5］	Zhao W, Wang J, Zhu H, et al. Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies［J］. Clin Rev Allergy Immunol, 2021,61（3）:351⁃362. doi: 10.1007/s12016⁃021⁃08882⁃1.
［6］	中国医师协会皮肤科医师分会自身免疫疾病亚专业委员会. 寻常型天疱疮诊断和治疗的专家建议［J］. 中华皮肤科杂志, 2016,49（11）:761⁃765. doi: 10.3760/cma.j.issn.0412⁃4030.2016. 11.01.
［7］	中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议（2020）［J］. 中华皮肤科杂志, 2020,53（1）:1⁃7. doi: 10.35541/cjd.20190703.
［8］	Zhang J, Huang X, Zhang Z, et al. Clinical observation of different doses of rituximab for the treatment of severe pemphigus: a single⁃center prospective cohort study［J］. J Am Acad Dermatol, 2023,88（2）:500⁃502. doi: 10.1016/j.jaad.2022. 06.1187.
［9］	陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则（2022版）［J］. 中华医学杂志, 2022,102（10）:697⁃703. doi: 10.3760/cma.j.cn112137⁃20211228⁃02911.
［10］	Ghaedi F, Etesami I, Aryanian Z, et al. Drug⁃induced pemphigus: a systematic review of 170 patients［J］. Int Immunopharmacol, 2021,92:107299. doi: 10.1016/j.intimp.2020. 107299.
［11］	Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts［J］. J Am Acad Dermatol, 2020,82（3）:575⁃585.e1. doi: 10. 1016/j.jaad.2018.02.021.
［12］	Chowdhury J, Datta PK, Chowdhury SN, et al. A clinicopathological study of pemphigus in Eastern India with special reference to direct immunofluorescence［J］. Indian J Dermatol, 2016,61（3）:288⁃294. doi: 10.4103/0019⁃5154.182422.
［13］	闫言, 徐浩翔, 晋红中, 等. ELISA技术检测寻常型天疱疮桥粒芯蛋白3抗体水平研究［J］. 临床皮肤科杂志, 2011,40（9）:529⁃531. doi: 10.3969/j.issn.1000⁃4963.2011.09.005.
［14］	Committee for Guidelines for the Management of Pemphigus Disease. Japanese guidelines for the management of pemphigus［J］. J Dermatol, 2014,41（6）:471⁃486. doi: 10.1111/1346⁃8138.12486.
［15］	Endo H, Rees TD, Matsue M, et al. Early detection and successful management of oral pemphigus vulgaris: a case report［J］. J Periodontol, 2005,76（1）:154⁃160. doi: 10.1902/jop.2005. 76.1.154.
［16］	Rahbar Z, Daneshpazhooh M, Mirshams⁃Shahshahani M, et al. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score［J］. JAMA Dermatol, 2014,150（3）:266⁃272. doi: 10.1001/jamadermatol.2013.8175.
［17］	Shimizu T, Takebayashi T, Sato Y, et al. Grading criteria for disease severity by pemphigus disease area index［J］. J Dermatol, 2014,41（11）:969⁃973. doi: 10.1111/1346⁃8138.12649.
［18］	Hébert V, Boulard C, Houivet E, et al. Large international validation of ABSIS and PDAI pemphigus severity scores［J］. J Invest Dermatol, 2019,139（1）:31⁃37. doi: 10.1016/j.jid.2018. 04.042.
［19］	Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus［J］. J Invest Dermatol, 2009,129（10）:2404⁃2410. doi: 10.1038/jid.2009.72.
［20］	Boulard C, Duvert Lehembre S, Picard⁃Dahan C, et al. Calculation of cut⁃off values based on the Autoimmune Bullous Skin Disorder Intensity Score （ABSIS） and Pemphigus Disease Area Index （PDAI） pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus［J］. Br J Dermatol, 2016,175（1）:142⁃149. doi: 10.1111/bjd.14405.
［21］	Harman KE, Seed PT, Gratian MJ, et al. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels［J］. Br J Dermatol, 2001,144（4）:775⁃780. doi: 10.1046/j.1365⁃2133.2001.04132.x.
［22］	Daneshpazhooh M, Chams⁃Davatchi C, Khamesipour A, et al. Desmoglein 1 and 3 enzyme⁃linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity［J］. J Eur Acad Dermatol Venereol, 2007,21（10）:1319⁃1324. doi: 10.1111/j.1468⁃3083. 2007.02254.x.
［23］	Lee MS, Yeh YC, Tu YK, et al. Network meta⁃analysis⁃based comparison of first⁃line steroid⁃sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus［J］. J Am Acad Dermatol, 2021,85（1）:176⁃186. doi: 10.1016/j.jaad. 2020.08.028.
［24］	Joly P, Maho⁃Vaillant M, Prost⁃Squarcioni C, et al. First⁃line rituximab combined with short⁃term prednisone versus prednisone alone for the treatment of pemphigus （Ritux 3）: a prospective, multicentre, parallel⁃group, open⁃label randomised trial［J］. Lancet, 2017,389（10083）:2031⁃2040. doi: 10.1016/S0140⁃6736（17）30070⁃3.
［25］	中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员会. 糖皮质激素治疗免疫相关性皮肤病专家共识（2018年）［J］. 中华临床免疫和变态反应杂志, 2018,12（1）:1⁃7. doi: 10.3969/j.issn.1673⁃8705.2018.01.001.
［26］	Mignard C, Maho⁃Vaillant M, Golinski ML, et al. Factors associated with short⁃term relapse in patients with pemphigus who receive rituximab as first⁃line therapy: a post hoc analysis of a randomized clinical trial［J］. JAMA Dermatol, 2020,156（5）:545⁃552. doi: 10.1001/jamadermatol.2020.0290.
［27］	中华医学会内分泌学分会, 中国内分泌代谢病专科联盟. 糖皮质激素类药物临床应用指导原则（2023版）［J］. 中华内分泌代谢杂志, 2023,39（4）:289⁃296. doi: 10.3760/cma.j.cn311282⁃20230116⁃00029.
［28］	Chovatiya R, Silverberg JI. Association of pemphigus and pemphigoid with osteoporosis and pathological fractures［J］. Arch Dermatol Res, 2020,312（4）:263⁃271. doi: 10.1007/s00403⁃019⁃02010⁃y.
［29］	Patel PM, Amber KT. The risk of Pneumocystis pneumonia in patients of autoimmune blistering disease⁃reply to letter entitled "Pemphigus management guidelines: a life⁃saving perspective"［J］. J Am Acad Dermatol, 2021,85（5）:e289. doi: 10.1016/j.jaad.2021.04.106.
［30］	Werth VP, Joly P, Mimouni D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris［J］. N Engl J Med, 2021,384（24）:2295⁃2305. doi: 10.1056/NEJMoa 2028564.
［31］	Russo I, Miotto S, Saponeri A, et al. Ultra⁃low dose rituximab for refractory pemghigus vulgaris: a pilot study［J］. Expert Opin Biol Ther, 2020,20（6）:673⁃678. doi: 10.1080/14712598.2020.172 7440.
［32］	Zhou X, Zhan T, Xu X, et al. The efficacy and safety of low⁃dose rituximab in the treatment of pemphigus vulgaris: a cohort study［J］. J Dermatolog Treat, 2024,35（1）:2302071. doi: 10.1080/09546634.2024.2302071.
［33］	Salopek TG, Logsetty S, Tredget EE. Anti⁃CD20 chimeric monoclonal antibody （rituximab） for the treatment of recalcitrant, life⁃threatening pemphigus vulgaris with implications in the pathogenesis of the disorder［J］. J Am Acad Dermatol, 2002,47（5）:785⁃788. doi: 10.1067/mjd.2002.126273.
［34］	Tedbirt B, Maho⁃Vaillant M, Houivet E, et al. Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first⁃line therapy: follow⁃up of the Ritux 3 Trial［J］. JAMA Dermatol, 2024,160（3）:290⁃296. doi: 10.1001/jamadermatol.2023.5679.
［35］	Kridin K, Mruwat N, Amber KT, et al. Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large⁃scale global cohort study［J］. Br J Dermatol, 2023,188（4）:499⁃505. doi: 10.1093/bjd/ljac118.
［36］	Chang Y, Chen X, Wang M, et al. A 10⁃year retrospective cohort analysis of rituximab for the treatment of pemphigus in a Chinese population［J］. J Am Acad Dermatol, 2021,85（6）:1643⁃1645. doi: 10.1016/j.jaad.2020.12.062.
［37］	张春燕, 邢丽秋, 钟蕾, 等. 2003⁃2019年北京市利妥昔单抗不良反应报告分析［J］. 中国新药杂志, 2020,29（18）:2157⁃2160. doi: 10.3969/j.issn.1003⁃3734.2020.18.020.
［38］	Daneshpazhooh M, Balighi K, Mahmoudi H, et al. Iranian guideline for rituximab therapy in pemphigus patients［J］. Dermatol Ther, 2019,32（5）:e13016. doi: 10.1111/dth.13016.
［39］	Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:1900⁃1913. doi: 10.1111/jdv.16752.
［40］	Chams⁃Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris［J］. J Eur Acad Dermatol Venereol, 2013,27（10）:1285⁃1292. doi: 10.1111/j.1468⁃3083.2012.04717.x.
［41］	Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo⁃controlled trial［J］. J Invest Dermatol, 2010,130（8）:2041⁃2048. doi: 10.1038/jid.2010.91.
［42］	Zhou X, Cheng L, Wang Y, et al. Effect of NUDT15 polymorphisms on early hematological safety of low⁃dose azathioprine in Chinese patients with pemphigus vulgaris: a prospective cohort study［J］. J Dermatol, 2022,49（4）:402⁃410. doi: 10.1111/1346⁃8138.16265.
［43］	中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议［J］. 中华皮肤科杂志, 2021,54（2）:116⁃121. doi: 10.35541/cjd.20200469.
［44］	Kolla A, Shah P, Cymerman R, et al. Assessing the use of methotrexate as an alternate therapy for pemphigus vulgaris and pemphigus foliaceus［J］. Dermatol Ther, 2022,35（8）:e15661. doi: 10.1111/dth.15661.
［45］	高奥, 郭代红, 姚翀, 等. 4826例免疫抑制剂及相关器官移植用药致药品不良反应自发报告分析［J］. 中国医院用药评价与分析, 2020,20（4）:484⁃488. doi: 10.14009/j.issn.1672⁃2124. 2020.04.026.
［46］	中国医师协会皮肤科医师分会自身免疫病专业委员会. 甲氨蝶呤治疗免疫相关性皮肤病专家共识［J］. 中华皮肤科杂志, 2021,54（5）:382⁃390. doi: 10.35541/cjd.20200796.
［47］	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识［J］. 中华皮肤科杂志, 2021,54（9）:765⁃770. doi: 10.35541/cjd.20210039.
［48］	Chu CY, Lee CH, Lee HE, et al. Taiwanese dermatological association （TDA） consensus for the management of pemphigus［J］. J Formos Med Assoc, 2023,122（7）:540⁃548. doi: 10.1016/j.jfma.2022.12.005.
［49］	Amagai M, Ikeda S, Shimizu H, et al. A randomized double⁃blind trial of intravenous immunoglobulin for pemphigus［J］. J Am Acad Dermatol, 2009,60（4）:595⁃603. doi: 10.1016/j.jaad. 2008.09.052.
［50］	Higashihara T, Kawase M, Kobayashi M, et al. Evaluating the efficacy of double⁃filtration plasmapheresis in treating five patients with drug⁃resistant pemphigus［J］. Ther Apher Dial, 2017,21（3）:243⁃247. doi: 10.1111/1744⁃9987.12557.
［51］	Schmidt E, Zillikens D. Immunoadsorption in dermatology［J］. Arch Dermatol Res, 2010,302（4）:241⁃253. doi: 10.1007/s00403⁃009⁃1024⁃9.
［52］	van Beek N, Eming R, Reuss A, et al. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus （IA⁃Pem Study）: a multicentre randomized controlled trial［J］. Br J Dermatol, 2024,190（5）:657⁃667. doi: 10.1093/bjd/ljad489.
［53］	Nosrati A, Hodak E, Mimouni T, et al. Treatment of pemphigus with rituximab: real⁃life experience in a cohort of 117 patients in Israel［J］. Dermatology, 2021,237（3）:450⁃456. doi: 10.1159/000513515.
［54］	Ahmed AR, Kalesinskas M, Kaveri SV. Restoring immune tolerance in pemphigus vulgaris［J］. Proc Natl Acad Sci U S A, 2024,121（5）:e2317762121. doi: 10.1073/pnas.2317762121.
［55］	Fuertes I, Guilabert A, Mascaró JM Jr, et al. Rituximab in childhood pemphigus vulgaris: a long⁃term follow⁃up case and review of the literature［J］. Dermatology, 2010,221（1）:13⁃16. doi: 10.1159/000287254.
［56］	Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017［J］. Br J Dermatol, 2017,177（5）:1170⁃1201. doi: 10.1111/bjd.15930.
［57］	Foster ML, Spaulding RT, Schadt CR. Neonatal pemphigus vulgaris［J］. JAMA Dermatol, 2021,157（2）:220. doi: 10.1001/jamadermatol.2020.3990.
［58］	Lan Y, Zhang H, Jin H. Pregnancy in pemphigus vulgaris: a systematic review［J］. Am J Reprod Immunol, 2024,91（1）:e13813. doi: 10.1111/aji.13813.
［59］	Kushner CJ, Concha J, Werth VP. Treatment of autoimmune bullous disorders in pregnancy［J］. Am J Clin Dermatol, 2018,19（3）:391⁃403. doi: 10.1007/s40257⁃018⁃0342⁃0.
［60］	中国医师协会皮肤科医师分会自身免疫性疾病专业委员会. 吗替麦考酚酯治疗免疫相关性皮肤病专家建议［J］. 中华皮肤科杂志, 2020,53（11）:869⁃874. doi: 10.35541/cjd.20200306.
［61］	中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员. 大疱性类天疱疮诊断和治疗的专家建议［J］. 中华皮肤科杂志, 2016,49（6）:384⁃387. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.06.003.
［62］	Tehranchi⁃Nia Z, Qureshi TA, Ahmed AR. Pemphigus vulgaris in older adults［J］. J Am Geriatr Soc, 1998,46（1）:92⁃94. doi: 10.1111/j.1532⁃5415.1998.tb01020.x.
［63］	Ingen⁃Housz⁃Oro S, Alexandre M, Le Roux⁃Villet C, et al. Pemphigus in elderly adults: clinical presentation, treatment, and prognosis［J］. J Am Geriatr Soc, 2012,60（6）:1185⁃1187. doi: 10.1111/j.1532⁃5415.2012.03987.x.
［64］	Zaraa I, Sellami A, Bouguerra C, et al. Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study［J］. J Eur Acad Dermatol Venereol, 2011,25（10）:1160⁃1167. doi: 10.1111/j.1468⁃3083.2010.03939.x.
［65］	Ruocco V, Ruocco E, Caccavale S, et al. Pemphigus vegetans of the folds （intertriginous areas）［J］. Clin Dermatol, 2015,33（4）:471⁃476. doi: 10.1016/j.clindermatol.2015.04.011.
［66］	Pritchett EN, Hejazi E, Cusack CA. Pruritic, pink scaling plaques on the face and trunk. Pemphigus erythematosus［J］. JAMA Dermatol, 2015,151（10）:1123⁃1124. doi: 10.1001/jamadermatol.2015.2103.
［67］	Hobbs LK, Noland MB, Raghavan SS, et al. Pemphigus erythematosus: a case series from a tertiary academic center and literature review［J］. J Cutan Pathol, 2021,48（8）:1038⁃1050. doi: 10.1111/cup.13992.
［68］	Kridin K, Patel PM, Jones VA, et al. IgA pemphigus: a systematic review［J］. J Am Acad Dermatol, 2020,82（6）:1386⁃1392. doi: 10.1016/j.jaad.2019.11.059.
［69］	Wang YM, Mao XM, Zhao WL, et al. The clinical, immunological and pathological features for relapse of pemphigus herpetiformis: a univariate analysis of 26 cases［J］. Br J Dermatol, 2020,182（3）:802⁃804. doi: 10.1111/bjd.18518.
［70］	Costa L, Cappel MA, Keeling JH. Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria［J］. Int J Dermatol, 2019,58（9）:997⁃1007. doi: 10.1111/ijd.14395.
［71］	Laws PM, Heelan K, Al⁃Mohammedi F, et al. Pemphigus herpetiformis: a case series and review of the literature［J］. Int J Dermatol, 2015,54（9）:1014⁃1022. doi: 10.1111/ijd.12582.
［72］	Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2023,37（6）:1118⁃1134. doi: 10.1111/jdv.18931.
［73］	Zhang X, Xiao Y, Li X, et al. Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab［J］. J Dermatol, 2024,51（7）:1026⁃1030. doi: 10.1111/1346⁃8138.17108.
［74］	Yanovsky RL, McLeod M, Ahmed AR. Treatment of pemphigus vulgaris: part 2 ⁃ emerging therapies［J］. Expert Rev Clin Immunol, 2019,15（10）:1061⁃1071. doi: 10.1080/1744666X.2020.1672539.

[1]	郝峰刘国艳. [开放获取] 光学相干断层扫描技术在皮肤科的应用进展[J]. 中华皮肤科杂志, 2024, 57(9): 853-857.
[2]	黄淑黛王大光. 甲与甲病的皮肤影像学进展[J]. 中华皮肤科杂志, 2024, 57(9): 866-869.
[3]	邹先彪陈锦纯曾悦郝轶. [开放获取] 超声检查在皮肤科的应用前景[J]. 中华皮肤科杂志, 2024, 57(9): 785-790.
[4]	向茜张凌燕钟琳高奕邱逦. 鲜红斑痣多模态超声表现及在光动力疗效评估中的应用研究[J]. 中华皮肤科杂志, 2024, 57(9): 801-806.
[5]	曾悦邵惠红林诗雯温柔邹先彪. 可穿戴远程会诊设备在常见皮肤病诊断中的应用[J]. 中华皮肤科杂志, 2024, 57(9): 797-800.
[6]	何兰马玲姜倩陈柳青陈红英. 非生殖器部位硬化性苔藓57例皮肤镜与反射式共聚焦显微镜影像特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 791-796.
[7]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[8]	中国中西医结合学会皮肤性病专业委员会中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 反射式共聚焦显微镜在常见黑素细胞性皮肤肿瘤中的应用专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(9): 775-784.
[9]	王瑞霞曲岩磊艾文锦闫琳曲才杰史同新. 非大疱性嗜中性红斑狼疮1例[J]. 中华皮肤科杂志, 2024, 57(9): 832-834.
[10]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 57(8): 743-746.
[11]	任伟琦邹雅茹潘敏. 大疱性类天疱疮患者继发感染危险因素的研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 770-772.
[12]	谢媛媛刘宇甄曾荣. 皮肤影像技术在寻常痤疮诊疗中的应用进展[J]. 中华皮肤科杂志, 2024, 57(8): 757-760.
[13]	夏曼琪邵蕾黄琼霄田歆梁毅敏黄婷梁景耀刘玉梅. 度普利尤单抗治疗结节性痒疹疗效与安全性的多中心回顾性分析[J]. 中华皮肤科杂志, 2024, 57(8): 679-684.
[14]	罗莉张博娜吴畏汤文静李岳华刘晓莉马雅楠李翠翠齐梦岩孙妮石琼. [开放获取] 308 nm准分子激光与308 nm准分子光治疗194例儿童白癜风的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2024, 57(8): 721-727.
[15]	刘青锋刘莲刁萍李晓雪张婷陈浩天刘绪蒋献. 鲜红斑痣相关综合征的诊疗进展[J]. 中华皮肤科杂志, 2024, 57(7): 656-660.

[开放获取] 中国天疱疮诊疗指南（2024版）

Guidelines for diagnosis and treatment of pemphigus in China （2024）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 74

相关文章 15

Metrics

本文评价

推荐阅读 10